Biopharma-focused hedge funds have cut back sharply on their private venture capital investments in 2022, but not to the extent of the tech-focused firms.
Yes, they all participated in fewer private fundraisings this year than they have in the past. But after a big burst in the first quarter, a few biopharma firms — many of which have dedicated venture funds — maintained the same level of activity in each of the three final quarters.
